|Category:||Emerging Biotech Company|
|Date:||April 25, 2023|
|Speaker:||Egle Katkeviciute, Chief Scientific Officer|
At Recolony, we focus our efforts in developing cancer therapies that primarily consist of selected commensal bacteria of the gut microbiota. By harnessing the potential of beneficial gut microbiota, Recolony aims to develop a completely new class of drugs for the treatment and prevention of cancer. Our aim is to shift the paradigm of cancer treatment away from single-target-drugs towards a gut microbiota guided activation of the immune system.